<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210608051514N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-15</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>Treatment of patients with type 1 bipolar disorder: clinical trial a double-blind study</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of transcranial  direct current stimulation on neurocognition in patients with type 1 bipolar disorder.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63457</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Subjects are selected from purposive sampling method and using simple randomization method, based on which the subjects are assigned to the two groups of control and experiment by tossing coins.This method is used for two-group clinical trials, according to which one group is called a lion, and the other is called a line, and thus the number of coin samples is tossed, Blinding description: In this study, the clinical evaluator and therapist will be blind to assigning subjects to control and experimental groups. In addition, we use the clinical evaluator separately for baseline assessments and follow-up, and the therapist separately for treatment.Subjects will also be assigned to control groups or blind experiments, so that subjects will not meet outside of the sessions and will visit at times when no other subjects will be present.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Bipolar disorder type 1. Condition 2: Bipolar disorder type 1, mania, manic depression, bipolar depression.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Treatment with stimulation of transcranial direct current stimulation with a cintensity of 2 mA for 20 minutes on the lateral dorsal forehead cortex will receive 10 sessions of 20 minutes in 3 consecutive weeks. Intervention 2: Control group: Intervention group: Treatment with stimulation of transcranial direct current stimulation with a cintensity of 2 mA for 40 seconds on the lateral dorsal forehead cortex will receive 10 sessions of 20 minutes in 3 consecutive.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All information of individuals except names and confidential information will be published at the end of the research. Publishable information including: therapeutic changes, results of questionnaires, statistical results of signal analysis, dose and medication used

When:
The results of this research will be published three months after the end of the research

To whom:
All researchers, researchers, colleagues, and others

Conditions:
To carry out similar projects and if all the material and intellectual rights of researchers are observed.

Where to obtain:
Contact the following email address to receive the documentation: Farahnaz Yousefi Master of Clinical Psychology farahnaz.yosefi76@gmail.com Address: Beheshti Hospital, Ark Gate, Chahar Ra Saadi, Zanjan Province

How to obtain:
The data will be provided to the applicant after receiving the e-mail of the applicant and observing the material and intellectual rights of the researchers.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Omidreza Heidari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Beheshti Hospital, Ark Gate, Chahar Ra Saadi, Zanjan Province</address>
        <city>zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7531974143</zip>
        <telephone>+98 21 8670 5698</telephone>
        <email>omid.orh@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farahnaz Yousefick[hk</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Beheshti Hospital, Ark Gate, Chahar Ra Saadi, Zanjan Province</address>
        <city>zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7531974143</zip>
        <telephone>02445731</telephone>
        <email>farahnaz.yosefi76@gmail.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having a diagnosis of bipolar disorder type one
Being in the euthanic phase based on assessment
The same dose and medicine
Stabilization in medical treatment for at least 4 weeks
Stabilization of drug and medicine dose during research</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having drug use and dependence up to 6 months before treatment
Having a history of neurological diseases
Having diseases related to the scalp
Having a history of head injuries
The presence of a device or tool in the head
Exclude from the study after absence in two consecutive sessions of treatment
Being left-handed</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>اختلال دو </hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>F39</hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Treatment with stimulation of transcranial direct current stimulation with a cintensity of 2 mA for 20 minutes on the lateral dorsal forehead cortex will receive 10 sessions of 20 minutes in 3 consecutive weeks.</i_keyword>
      <i_keyword>Control group: Intervention group: Treatment with stimulation of transcranial direct current stimulation with a cintensity of 2 mA for 40 seconds on the lateral dorsal forehead cortex will receive 10 sessions of 20 minutes in 3 consecutive</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Executive performance: Executive performance refers to the ability to integrate thought and action to achieve a goal. Timepoint: pre test_post test_3mounth follow up. Method of measurement: The score that a person gets from the second part of the sequence test.</prim_outcome>
      <prim_outcome>Spatial visual memory: means the ability to store and manipulate information in consciousness for a short period of time. Timepoint: pre test_post test_3mounth follow up. Method of measurement: The score that a person gets from the test of complex images.</prim_outcome>
      <prim_outcome>Delayed Recognition: The ability to retrieve specific information after a period of time or distraction. Timepoint: pre test_post test_3mounth follow up. Method of measurement: The score that a person gets from the test of complex images.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Attention is a cognitive process in which the mind focuses on a specific stimulus or stimuli from the environment and other environmental stimuli are ignored. Timepoint: pre test_post test_3mounth follow up. Method of measurement: The score that a person gets from the sequence test in the first part.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-02</approval_date>
        <contact_name>Ethics Committee of Zanjan University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti Hospital, Ark Gate, Saadi Crossroads, Zanjan Province zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
